SCPI — Income Statement (Laba Rugi)
Laporan Keuangan Ringkasan laba rugi, neraca, dan arus kas — SCPI PT Organon Pharma Indonesia Tbk
| Dalam Jutaan IDR | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total Pendapatan | 863,806 | 4,122,385 | 2,907,781 | 1,733,567 | 886,307 | 2,895,902 | 2,254,965 | 1,350,439 | 692,835 |
| Total Beban Pokok Penjualan | (748,842) | (3,682,728) | (2,557,319) | (1,534,071) | (769,434) | (2,595,140) | (1,979,178) | (1,180,584) | (617,596) |
| Laba Kotor | 114,964 | 439,657 | 350,462 | 199,495 | 116,873 | 300,763 | 275,787 | 169,855 | 75,239 |
| Total Beban Usaha | (12,859) | (67,322) | (47,650) | (30,488) | (13,567) | (66,190) | (44,055) | (25,433) | (13,263) |
| Laba Usaha | 102,105 | 372,335 | 302,813 | 169,007 | 103,306 | 234,572 | 231,732 | 144,422 | 61,976 |
| Penghasilan/Beban Lain-Lain | 3,412 | 11,660 | 8,450 | 3,698 | 2,622 | 7,098 | 2,914 | 700 | (3) |
| Laba Sebelum Pajak | 105,517 | 383,995 | 311,263 | 172,705 | 105,929 | 241,671 | 234,645 | 145,122 | 61,974 |
| Beban Pajak Penghasilan | (19,273) | (93,289) | (73,278) | (41,011) | (24,674) | (55,055) | (54,669) | (33,513) | (14,459) |
| Laba Bersih Dari Operasi Yang Dilanjutkan | 86,244 | 290,706 | 237,985 | 131,693 | 81,255 | 186,616 | 179,977 | 111,609 | 47,515 |
| Hak Minoritas | - | - | - | - | - | - | - | - | - |
| Penyesuaian Proforma | - | - | - | - | - | - | - | - | - |
| Laba Bersih Tahun Berjalan | 86,244 | 290,706 | 237,985 | 131,693 | 81,255 | 186,616 | 179,977 | 111,609 | 47,515 |
| Pendapatan Komprehensif Lain | - | 7,268 | - | - | - | 5,941 | - | - | - |
| Jumlah Laba Komprehensif | 86,244 | 297,974 | 237,985 | 131,693 | 81,255 | 192,557 | 179,977 | 111,609 | 47,515 |
| Laba Bersih Yang Dapat Diatribusikan | 86,244 | 290,706 | 237,985 | 131,693 | 81,255 | 186,616 | 179,977 | 111,609 | 47,515 |
| Laba Komprehensif Yang Dapat Diatribusikan | 86,244 | 297,974 | 237,985 | 131,693 | 81,255 | 192,557 | 179,977 | 111,609 | 47,515 |
Key Ratios — SCPI
| Rasio | Q1 2026 ×4 | Q4 2025 | Q3 2025 ×1⅓ | Q2 2025 ×2 | Q1 2025 ×4 | Q4 2024 | Q3 2024 ×1⅓ | Q2 2024 ×2 | Q1 2024 ×4 |
|---|---|---|---|---|---|---|---|---|---|
| Profitabilitas | |||||||||
| Gross Margin (%) | 13.31% | 10.67% | 12.05% | 11.51% | 13.19% | 10.39% | 12.23% | 12.58% | 10.86% |
| Operating Margin (%) | 11.82% | 9.03% | 10.41% | 9.75% | 11.66% | 8.10% | 10.28% | 10.69% | 8.95% |
| Net Margin (%) | 9.98% | 7.05% | 8.18% | 7.60% | 9.17% | 6.44% | 7.98% | 8.26% | 6.86% |
| ROE (%) | 24.34% | 21.84% | 24.97% | 22.61% | 29.17% | 18.07% | 23.52% | 23.45% | 21.40% |
| ROA (%) | 15.44% | 12.77% | 14.82% | 13.76% | 16.89% | 11.41% | 13.81% | 13.42% | 11.67% |
| Per Lembar Saham | |||||||||
| EPS (Rp) | 95.826,74 | 80.751,56 | 88.142,62 | 73.162,92 | 90.282,85 | 51.837,67 | 66.657,98 | 62.005,16 | 52.793,99 |
| BVPS (Rp) | 393.672,73 | 369.716,05 | 353.052,58 | 323.527,08 | 309.516,33 | 286.945,62 | 283.451,16 | 264.460,25 | 246.656,16 |
| Valuasi | |||||||||
| PER (x) | 0.30x | 0.36x | 0.33x | 0.40x | 0.32x | 0.56x | 0.44x | 0.47x | 0.55x |
| PBV (x) | 0.07x | 0.08x | 0.08x | 0.09x | 0.09x | 0.10x | 0.10x | 0.11x | 0.12x |
| Struktur Modal | |||||||||
| DER (x) | 0.58x | 0.71x | 0.68x | 0.64x | 0.73x | 0.58x | 0.70x | 0.75x | 0.83x |